Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ponesimod

FDA-approved product (tablet, oral), marketed as Ponvory.

Registered studies
22
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ponesimod
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Multiple sclerosis
  • Relapsing-remitting multiple sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sphingosine-1-phosphate (s1p) receptor modulators
FDA pharmacologic class
Sphingosine 1-phosphate Receptor Modulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

22registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ponesimod in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ponesimod with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis

    NCT07686081 · start 2026-09

    Registered record
    Registry ID
    NCT07686081
    Conditions
    Ulcerative Colitis (UC)
    Interventions
    Ponesimod; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-09
    Completion
    2029-08
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis (UC)
    InterventionPonesimod; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

    NCT07362017 · start 2026-02-17

    Registered record
    Registry ID
    NCT07362017
    Conditions
    Moderate-to-severe Chronic Plaque Psoriasis
    Interventions
    Ponesimod
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-02-17
    Completion
    2028-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate-to-severe Chronic Plaque Psoriasis
    InterventionPonesimod
    PhasePhase 3
    Registry statusRecruiting

  • A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS

    NCT06715605 · start 2025-04-30

    Registered record
    Registry ID
    NCT06715605
    Conditions
    Multiple Sclerosis
    Interventions
    tolerogenic dendritic cells (tolDC); Standard-of-care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2025-04-30
    Completion
    2027-10-29
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    Interventiontolerogenic dendritic cells (tolDC); Standard-of-care
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of Ponesimod in Healthy Adult Participants

    NCT05552196 · start 2022-10-18

    Registered record
    Registry ID
    NCT05552196
    Conditions
    Healthy
    Interventions
    Ponesimod; Carbamazepine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-10-18
    Completion
    2023-03-29
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPonesimod; Carbamazepine
    PhasePhase 1
    Registry statusCompleted

  • A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

    NCT05688436 · start 2021-09-24

    Registered record
    Registry ID
    NCT05688436
    Conditions
    Multiple Sclerosis
    Interventions
    Diroximel Fumarate; Alemtuzumab; Fingolimod; Glatiramer acetate; Interferon beta; Natalizumab; Ocrelizumab; Ofatumumab; Ozanimod; Peginterferon beta-1a; Ponesimod; Siponimod
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-09-24
    Completion
    2031-01-17
    Enrolment
    1,178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionDiroximel Fumarate; Alemtuzumab; Fingolimod; Glatiramer acetate +8 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

    NCT03882255 · start 2019-03-20

    Registered record
    Registry ID
    NCT03882255
    Conditions
    Healthy
    Interventions
    Ponesimod dose range (2 - 20 mg); Placebo Propranolol; Propranolol 80 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-03-20
    Completion
    2019-08-26
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPonesimod dose range (2 - 20 mg); Placebo Propranolol; Propranolol 80 mg
    PhasePhase 1
    Registry statusCompleted

  • Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

    NCT03535298 · start 2019-01-03

    Registered record
    Registry ID
    NCT03535298
    Conditions
    Multiple Sclerosis, Relapsing-Remitting
    Interventions
    Early Highly Effective Therapies Group; Escalation Therapies Group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2019-01-03
    Completion
    2027-07-30
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis, Relapsing-Remitting
    InterventionEarly Highly Effective Therapies Group; Escalation Therapies Group
    PhasePhase 4
    Registry statusActive not recruiting

  • Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

    NCT05762003 · start 2019-01-01

    Registered record
    Registry ID
    NCT05762003
    Conditions
    Multiple Sclerosis
    Interventions
    interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-01
    Completion
    2021-12-31
    Enrolment
    17,478

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    Interventioninterferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
    PhaseNot recorded
    Registry statusCompleted

  • Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

    NCT03500328 · start 2018-05-02

    Registered record
    Registry ID
    NCT03500328
    Conditions
    Multiple Sclerosis, Relapsing-Remitting
    Interventions
    Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq; Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2018-05-02
    Completion
    2026-09
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis, Relapsing-Remitting
    InterventionNatalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq; Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
    PhaseNot applicable
    Registry statusActive not recruiting

  • Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

    NCT03232073 · start 2017-07-05

    Registered record
    Registry ID
    NCT03232073
    Conditions
    Multiple Sclerosis
    Interventions
    Ponesimod
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-07-05
    Completion
    2024-01-16
    Enrolment
    877

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionPonesimod
    PhasePhase 3
    Registry statusCompleted

  • Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

    NCT02907177 · start 2017-03-30

    Registered record
    Registry ID
    NCT02907177
    Conditions
    Multiple Sclerosis
    Interventions
    Ponesimod; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-03-30
    Completion
    2020-03-26
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionPonesimod; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

    NCT02461134 · start 2016-09-29

    Registered record
    Registry ID
    NCT02461134
    Conditions
    Chronic Graft Versus Host Disease
    Interventions
    Ponesimod
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-09-29
    Completion
    2017-03-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Graft Versus Host Disease
    InterventionPonesimod
    PhasePhase 2
    Registry statusTerminated

  • Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

    NCT02425644 · start 2015-06-04

    Registered record
    Registry ID
    NCT02425644
    Conditions
    Multiple Sclerosis
    Interventions
    ponesimod; teriflunomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06-04
    Completion
    2019-05-16
    Enrolment
    1,133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    Interventionponesimod; teriflunomide
    PhasePhase 3
    Registry statusCompleted

  • Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects

    NCT02068235 · start 2014-08

    Registered record
    Registry ID
    NCT02068235
    Conditions
    Healthy
    Interventions
    Ponesimod 5mg i.v.; Ponesimod i.v.; Ponesimod 10 mg tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-08
    Completion
    2014-11
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPonesimod 5mg i.v.; Ponesimod i.v.; Ponesimod 10 mg tablet
    PhasePhase 1
    Registry statusCompleted

  • Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

    NCT02136888 · start 2011-08

    Registered record
    Registry ID
    NCT02136888
    Conditions
    Healthy
    Interventions
    Ponesimod Placebo; Moxifloxacin Placebo; Ponesimod 10 mg; Ponesimod 20 mg; Ponesimod 40 mg; Ponesimod 60 mg; Ponesimod 80 mg; Ponesimod 100 mg; Moxifloxacin 400 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-02
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPonesimod Placebo; Moxifloxacin Placebo; Ponesimod 10 mg; Ponesimod 20 mg +5 more
    PhasePhase 1
    Registry statusCompleted